Literature DB >> 11777639

Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy.

Akmal Safwat1, Søren M Bentzen, Ingela Turesson, Jolyon H Hendry.   

Abstract

BACKGROUND: The large patient-to-patient variability in the grade of normal tissue injury after a standard course of radiotherapy is well established clinically. A better understanding of this individual variation may provide valuable insights into the pathogenesis of radiation damage and the prospects of predicting the outcome.
PURPOSE: To estimate the relative importance of the stochastic vs. patient-related components of variability in the expression of radiation-induced normal tissue damage. METHODS AND MATERIALS: The study data were selected from the dose fractionation studies of Turesson in Gothenburg. Patients treated with bilateral internal mammary fields, who completed at least 10 years of follow-up, were included. The material included 22 different fractionation schedules (11 on each side). Telangiectasia was graded on an arbitrary 6-point scale using clinical photographs of the irradiated fields. For each field, in each patient, a curve showing the grade of telangiectasia as a function of time was constructed. A measure of radioresponsiveness was obtained from the difference between the area under the curve (AUC) for a specific field in an individual patient minus the mean AUC of fields receiving the same dose fractionation schedule. As a confirmatory procedure, the same analysis was repeated with a weighted area under the curve (WAUC) approach, in which the time spent at or above each of the 5 nonzero grades was calculated for each field in each patient. These times were used as explanatory variables in a linear regression analysis of biological equivalent dose to establish statistically the weight of each grade providing the optimal relationship between dose and effect. Using these regression coefficients, the weighted area under the grade-time curve (WAUC) was estimated.
RESULTS: The AUC was significantly correlated with the isoeffective dose in 2-Gy fractions (ID2). An analysis of variance components, using the maximum likelihood method, showed that 90% (with 95% confidence limits 65% and 100%) of the variance in radioresponsiveness in the right-sided field was explained by the radioresponsiveness on the left-sided field. Through the linear regression analysis between the AUC and the ID2, it was estimated that patients with a reaction that is 1 SD from the population mean would require a dose modification of approximately 23 Gy (from the group mean of 56 Gy) to give them a level of reaction similar to the group average. Similarly, the WAUC was significantly correlated with the ID2, and 81% (with 95% confidence limits 49% and 100%) of the variance in radioresponsiveness in the right-sided field was explained by the radioresponsiveness on the left-sided field. Patients with a reaction that is 1 SD from the population mean would require a dose modification of approximately 21 Gy (from the group mean of 56 Gy) to give them a level of reaction similar to the group average.
CONCLUSION: For a given fractionation schedule, patient-related factors explain 81-90% of the patient-to-patient variation in telangiectasia level seen after radiotherapy. The remaining 10-19% are explained by stochastic effects. This observation encourages further research into genetic or phenotypic assays of normal tissue radioresponsiveness.

Entities:  

Mesh:

Year:  2002        PMID: 11777639     DOI: 10.1016/s0360-3016(01)02690-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Predicting toxicity from radiation therapy--it's genetic, right?

Authors:  Chris R Kelsey; Barry S Rosenstein; Lawrence B Marks
Journal:  Cancer       Date:  2011-12-05       Impact factor: 6.860

2.  Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.

Authors:  Lindsay M Morton; Luisel Ricks-Santi; Catharine M L West; Barry S Rosenstein
Journal:  Int J Part Ther       Date:  2018-09-21

Review 3.  Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.

Authors:  Søren M Bentzen; Matthew Parliament; Joseph O Deasy; Adam Dicker; Walter J Curran; Jacqueline P Williams; Barry S Rosenstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 4.  Radiotherapy and wound healing.

Authors:  Emma-Louise Dormand; Paul E Banwell; Timothy E E Goodacre
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

Review 5.  Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors:  Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal:  Cancer Discov       Date:  2014-01-17       Impact factor: 39.397

6.  Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer.

Authors:  Sarah L Kerns; Harry Ostrer; Richard Stock; William Li; Julian Moore; Alexander Pearlman; Christopher Campbell; Yongzhao Shao; Nelson Stone; Lynda Kusnetz; Barry S Rosenstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-01       Impact factor: 7.038

Review 7.  Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity.

Authors:  Barry S Rosenstein
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

8.  Genetic variation in radiation-induced expression phenotypes.

Authors:  Candace R Correa; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2004-09-09       Impact factor: 11.025

Review 9.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 10.  Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?

Authors:  Carsten Herskind; Christopher J Talbot; Sarah L Kerns; Marlon R Veldwijk; Barry S Rosenstein; Catharine M L West
Journal:  Cancer Lett       Date:  2016-03-02       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.